These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23848430)

  • 1. Emerging antithrombotic drugs for acute coronary syndrome.
    Shimada YJ; Giugliano RP
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):307-18. PubMed ID: 23848430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New antiplatelet agents: why they are needed.
    Franchini M; Mannucci PM
    Eur J Intern Med; 2009 Dec; 20(8):733-8. PubMed ID: 19892299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ticagrelor--a new platelet aggregation inhibitor in patients with acute coronary syndromes. An improvement of other inhibitors?
    Kowalczyk M; Banach M; Mikhailidis DP; Hannam S; Rysz J
    Med Sci Monit; 2009 Dec; 15(12):MS24-30. PubMed ID: 19946242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in antiplatelet therapy for ACS and PCI.
    Moliterno DJ
    J Interv Cardiol; 2008 Dec; 21 Suppl 1():S18-24. PubMed ID: 19090933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold?
    Huber K; Bates ER; Valgimigli M; Wallentin L; Kristensen SD; Anderson JL; Lopez Sendon JL; Tubaro M; Granger CB; Bode C; Ohman EM; Steg PG
    Am Heart J; 2014 Nov; 168(5):611-21. PubMed ID: 25440788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging antiplatelet therapy for coronary artery disease and acute coronary syndrome.
    Packard KA; Campbell JA; Knezevich JT; Davis EM
    Pharmacotherapy; 2012 Mar; 32(3):244-73. PubMed ID: 22392457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging oral antiplatelet therapies for acute coronary syndromes.
    Pollack CV
    Hosp Pract (1995); 2010 Nov; 38(4):29-37. PubMed ID: 21068524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical overview of promising nonthienopyridine antiplatelet agents.
    Angiolillo DJ; Guzman LA
    Am Heart J; 2008 Aug; 156(2 Suppl):S23-8. PubMed ID: 18657683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on antiplatelet therapy in acute coronary syndromes: what do new drugs bring into clinical practice?
    Heras M; del Río A
    Am J Cardiovasc Drugs; 2009; 9 Suppl 1():13-7. PubMed ID: 20000883
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients.
    Tcheng JE; Mackay SM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):83-91. PubMed ID: 22316323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiplatelet therapy prasugrel: a novel platelet ADP P2Y12 receptor antagonist.
    Mousa SA; Jeske WP; Fareed J
    Clin Appl Thromb Hemost; 2010 Apr; 16(2):170-6. PubMed ID: 20299391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.
    Ganetsky VS; Hadley DE; Thomas TF
    Pharmacotherapy; 2014 Jun; 34(6):590-604. PubMed ID: 24338703
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiplatelet intervention in acute coronary syndrome.
    Arora RR; Rai F
    Am J Ther; 2009; 16(5):e29-40. PubMed ID: 19092648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiplatelet therapy in acute coronary syndrome (ACS): applying new science to clinical decisions.
    Becker RC; Gibson CM; Jennings LK; Morrow DA
    Am J Cardiol; 2010 Oct; 106(8):S2-3. PubMed ID: 20920638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cangrelor: a review on pharmacology and clinical trial development.
    Franchi F; Rollini F; Muñiz-Lozano A; Cho JR; Angiolillo DJ
    Expert Rev Cardiovasc Ther; 2013 Oct; 11(10):1279-91. PubMed ID: 24138516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cangrelor: a novel P2Y12 receptor antagonist.
    Norgard NB
    Expert Opin Investig Drugs; 2009 Aug; 18(8):1219-30. PubMed ID: 19604122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
    Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
    Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis In Myocardial Infarction 51).
    Krantz MJ; Kaul S
    J Am Coll Cardiol; 2013 Aug; 62(9):777-81. PubMed ID: 23747777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic evaluation of rivaroxaban for the treatment of acute coronary syndromes.
    Gopalakrishnan L; Kumar V; Kohli P; Singh P; Rastogi U; Gibson CM
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):889-900. PubMed ID: 22577900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.